524916-42-5

Basic information

• Product Name: 4-AMino-3-(4,4,5,5-tetraMethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid Methyl ester
• Synonyms: 4-AMino-3-(4,4,5,5-tetraMethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid Methyl ester;methyl 4-amino-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate
• CAS NO: 524916-42-5
• Molecular Formula: C₁₄H₂₀BNO₄
• Molecular Weight: 277.1239
• Mol File: 524916-42-5.mol

Chemical Properties

• Melting Point: 189-191 °C
• Boiling Point: 432.0±35.0 °C(Predicted)
• Appearance: /
• Density: 1.13±0.1 g/cm3(Predicted)
• PKA: 1.76±0.10(Predicted)
• CAS DataBase Reference: 4-AMino-3-(4,4,5,5-tetraMethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMino-3-(4,4,5,5-tetraMethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid Methyl ester(524916-42-5)
• EPA Substance Registry System: 4-AMino-3-(4,4,5,5-tetraMethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid Methyl ester(524916-42-5)

Safety Data

• Hazardous Substances Data: 524916-42-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
4-Amino-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid methyl ester is used as a reagent in the preparation of various pharmaceuticals and agrochemicals due to its unique chemical properties.
Used in Transition Metal Catalysis:
4-Amino-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid methyl ester is used as a ligand in transition metal catalysis, which is crucial for various chemical reactions and processes.
Used in Material Science:
4-Amino-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid methyl ester is also employed in the development of new materials, showcasing its versatility in the field of chemistry.

Upstream product

• 19718-49-1 4-amino-3-iodobenzoic acid methyl ester 
• 106896-49-5 methyl 4-amino-3-bromobenzoate 
• 73183-34-3 bis(pinacol)diborane 
• 25015-63-8 4,4,5,5-tetramethyl-[1,3,2]-dioxaboralane 

Downstream Products

• 1204414-22-1 methyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-[(2-thienylacetyl)amino]benzoate 
• 42901-11-1 methyl 4-amino-3-benzyl-benzoate 

Relevant articles and documents

HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS

The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1, A, X1, X2, R1, R2, and R3 are described herein.

FACTOR XIa INHIBITORS

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma Kallikrein.

New synthetic approach to paullones and characterization of their SIRT1 inhibitory activity

A series of 7,12-dihydroindolo[3,2-d][1]benzazepine-6(5H)-ones (paullones) substituted at C9/C10 (Br) and C2 (Me, CF3, CO2Me) have been synthesized by a one-pot Suzuki-Miyaura cross-coupling of an o-aminoarylboronic acid and methyl 2-iodoindoleacetate followed by intramolecular amide formation. Other approaches to the paullone scaffold based on Pd-catalyzed C-H activation were unsuccessful. In vitro enzymatic assay with recombinant human SIRT-1 indicated a strong inhibitory profile for the series, in particular the analogue with a methoxycarbonyl group at C2 and a bromine at C9. These compounds are, in general, inducers of granulocyte differentiation of the U937 acute leukemia cell line and cause a marked increase in pre-G1 of the cell cycle.

Observations on the deprotection of pinanediol and pinacol boronate esters via fluorinated intermediates

(Chemical Equation Presented) Methods for the deprotection of pinanediol and pinacol esters of various boronic acids via fluoroborane intermediates were evaluated. Treatment of the boronate esters with potassium hydrogen difluoride normally gives trifluor

Alpha-helix mimicry by a class of organic molecules

The present invention provides methods for making compounds and methods for using the compounds to disrupt or inhibit protein-protein interactions. Also provided are pharmaceutical compositions comprising the compounds of the current invention.